Vtesse

11 articles about Vtesse

• 

  Parents Accuse Vtesse, Sucampo of Stealing Data From Their Sick Children

  1/9/2018

  The suit, filed in Nevada Friday, comes after Vtesse was purchased by Sucampo for $200 million in April.

• Sucampo Pays $200 Million Upfront for Rare Disease Biotech Vtesse

  4/3/2017

• Vtesse Completes Enrollment Of Phase IIb/III Pivotal Clinical Trial Of VTS-270 In Niemann-Pick Type C1 Disease

  3/15/2017

• Vtesse Announces Dosing Of First Patient In Australia In Phase 2b/3 Clinical Trial Of VTS-270 In Niemann-Pick Type C1 Disease

  1/11/2017

• Vtesse Announces Appointment Of Jason Meyenburg As Chief Commercial Officer

  1/4/2017

• Vtesse Receives Rare Pediatric Disease Designation By The FDA For VTS-270 For The Treatment Of Niemann-Pick Type C1 Disease

  11/29/2016

• Medicines And Healthcare Products Regulatory Agency ("MHRA") Designates VTS-270 As A Promising Innovative Medicine

  11/2/2016

• Vtesse Announces Dosing Of First Patient In Germany For Phase 2b/3 Clinical Trial Of VTS-270 In Niemann-Pick Type C1 Disease

  10/5/2016

• Vtesse Bags Another $17 Million to Support Further Product Development and Expand Ongoing Clinical Trials

  7/25/2016

• Vtesse Advances Phase 2b/3 Clinical Trial Of VTS-270 In Niemann-Pick Type C1 Disease With Dose Selection For Evaluation In Second And Final Portion Of Trial And Expansion Into Europe

  5/23/2016

• Vtesse Announces Phase 1/2 Clinical Data Showing Slowing Of Disease Progression From VTS-270 Treatment For Niemann-Pick Type C1 Disease

  3/4/2016